$580 Million is the total value of Aisling Capital LLC's 22 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2015 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.